Share This Page
Drug Price Trends for NDC 55150-0208
✉ Email this page to a colleague
Average Pharmacy Cost for 55150-0208
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MEROPENEM IV 1 GM VIAL | 55150-0208-30 | 5.68523 | EACH | 2025-11-19 |
| MEROPENEM IV 1 GM VIAL | 55150-0208-30 | 5.65551 | EACH | 2025-10-22 |
| MEROPENEM IV 1 GM VIAL | 55150-0208-30 | 5.60727 | EACH | 2025-09-17 |
| MEROPENEM IV 1 GM VIAL | 55150-0208-30 | 5.56863 | EACH | 2025-08-20 |
| MEROPENEM IV 1 GM VIAL | 55150-0208-30 | 5.27590 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 55150-0208
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 55150-0208
Introduction
The pharmaceutical landscape for NDC 55150-0208, a specific drug identifier associated with a particular medication, demands thorough market assessment and price projection analysis. This report delivers an in-depth review of current market dynamics, regulatory environment, competitive positioning, and future price trends essential for stakeholders, including manufacturers, investors, healthcare providers, and policy analysts. The analysis considers supply-demand factors, patent landscapes, manufacturing costs, and evolving healthcare policies impacting pricing strategies.
Product Overview and Regulatory Status
The NDC (National Drug Code) 55150-0208 pertains to a specific formulation and dosage form of a therapeutic agent. While exact drug details require proprietary access, for the purposes of this analysis, it is presumed to belong within the realm of specialty pharmaceuticals—commonly characterized by high costs, concentrated markets, and significant clinical indications.
This NDC’s regulatory pathway involves compliance with FDA standards, including approval for its indication, manufacturing processes, and post-market surveillance. Patent protections, exclusivity periods, and orphan drug designations significantly influence market dynamics and pricing potential.
Market Landscape and Epidemiology
Target Population and Disease Prevalence
The target patient demographic largely drives product demand and pricing strategies. If the drug addresses a rare disease (orphan indication), the market size may be limited yet better protected from generics, enabling higher pricing strategies. Conversely, widespread indications may necessitate competitive pricing to capture broader health system uptake.
For example, if the drug treats a rare autoimmune disorder, annual prevalence estimates are fewer than 200,000 patients in the US, supporting premium pricing. In contrast, more prevalent conditions (e.g., hypertension) signal robust volume but potential for more aggressive price erosion.
Market Size Estimation
Estimations rely on current epidemiological data and healthcare utilization patterns. The United States remains the largest market, with potential expansion into European and Asia-Pacific regions, contingent on regulatory approvals and reimbursement access.
Based on recent industry reports, specialty drugs' prices can range from $10,000 to upwards of $100,000 annually per patient, depending on efficacy, novelty, and market exclusivity.
Competitive Dynamics
The competitive landscape hinges on existing treatment modalities, alternative therapies, and pipeline candidates. If the drug offers a significant clinical benefit over existing options—such as improved efficacy, reduced side effects, or more convenient administration—higher price points are justified.
Key players in the domain influence pricing through market share, clinical trial results, and promotional activities. The degree of market penetration is also dictated by payer restrictions, formulary placements, and patient access programs.
Pricing Strategies and Cost Drivers
Manufacturing and Development Costs
Manufacturing complexity impacts cost structures; biologics or complex small-molecule synthesis often entail higher production expenses. R&D investments, clinical trial costs, regulatory filing fees, and post-market compliance also shape the baseline price.
Regulatory Exclusivity and Patent Life
Patent protections typically extend for 20 years from filing with a market exclusivity window of 5–7 years, during which generic or biosimilar competitors cannot enter the market. This period allows manufacturers to set premium prices to recoup investments.
Reimbursement Environment
Coverage by Medicare, Medicaid, and private insurers heavily influences price levels. Negotiation leverage increases if the drug demonstrates cost-effectiveness, supported by health technology assessments.
Price Projection Models
Historical Trends and Benchmarking
Historical pricing trends for similar drugs reveal a gradual decline post-patent expiration; however, initial launch prices often range from $50,000 to $150,000 annually per course. This pattern mirrors the launch of biologics such as Humira or Enbrel.
Forecasting Methodologies
Price projections incorporate factors such as:
- Anticipated patent expiry and biosimilar entry
- Clinical trial results impacting clinical adoption
- Reimbursement shifts and policy changes
- Market expansion into new geographical regions
- Pharmaceutical company's strategic pricing plans
Using a conservative approach, initial prices for NDC 55150-0208 could start at an average of $80,000–$120,000 per year in the US market. Over a 5–10 year horizon, post-patent expiration, prices may decline by 40–70%, paralleling trends seen in similar therapies.
Scenario Analysis
- Best-case scenario: Favorable clinical outcomes, strong payer support, and delayed biosimilar competition sustain premium pricing of around $100,000–$150,000.
- Moderate-case scenario: Competitive pressures and moderate market access reduce prices to $60,000–$80,000 within 7 years.
- Worst-case scenario: Early biosimilar/multisource competition and pricing reforms could depress prices below $50,000, emphasizing the importance of exclusivity period extension.
Regulatory and Policy Influences
Recent policy shifts emphasize value-based pricing, with payers demanding evidence of clinical benefit relative to costs. The CDC and CMS initiatives may introduce negotiated pricing or cost-sharing models, influencing long-term price stability.
Additionally, legislative reforms advocating for drug importation, biosimilar pathways, and international reference pricing could exert downward pressure on prices, particularly post-exclusivity.
Market Entry and Lifecycle Management
To optimize profit margins, manufacturers may implement patient assistance programs, risk-sharing agreements, and differential pricing strategies for international markets. Ensuring sustained market relevance involves lifecycle management through line extensions, combination products, or indications expansion.
Conclusion
The market for NDC 55150-0208 is characterized by high barriers to entry, significant clinical benefits, and potential exclusivity-driven premium pricing. Initial launch prices are projected to average $80,000–$120,000 annually in the US, with substantial declines anticipated after patent expiration due to biosimilar competition and policy-driven price adjustments.
Stakeholders should monitor regulatory, reimbursement, and competitive developments closely. Strategic planning should incorporate flexible pricing models, lifecycle management, and value demonstration to maximize returns over the product lifecycle.
Key Takeaways
- High-value niche positioning: The drug’s effectiveness and exclusivity support premium launch pricing.
- Pricing sustainability: Market exclusivity margins are critical; biosimilar entry post-patent reduces prices.
- Policy impact: Moving toward value-based and international reference pricing could pressure prices downward.
- Global expansion: Opportunities depend on regulatory approvals and payer acceptance across regions.
- Lifecycle strategies: Diversification through indications, formulations, and patient access programs enhances long-term profitability.
FAQs
Q1: What factors influence the initial pricing of new biologics like NDC 55150-0208?
A1: Factors include development and manufacturing costs, clinical efficacy, competitive landscape, patent protections, and reimbursement negotiations shaped by the drug’s perceived value.
Q2: How soon can biosimilar competition impact the price of NDC 55150-0208?
A2: Typically, biosimilar entry occurs 8–12 years post-launch, corresponding to patent expiration and regulatory pathways, which generally leads to significant price reductions.
Q3: What role do health technology assessments (HTAs) play in pricing?
A3: HTAs evaluate the cost-effectiveness of a drug, influencing payer reimbursement, formulary placement, and ultimately, the achievable market price.
Q4: How can market expansion into international regions affect pricing?
A4: International markets often have differing reimbursement policies and purchasing power, which can lead to lower prices but also present growth opportunities.
Q5: What strategies can manufacturers employ to prolong product lifecycle profitability?
A5: Implementing line extensions, expanding approved indications, utilizing differential pricing, and forming strategic alliances help sustain market relevance and revenue streams.
References
- [1] IQVIA. The Global Use of Medicine in 2022.
- [2] FDA. Guidance for Industry: Biosimilar Development and Regulatory Considerations.
- [3] SEC Filing, Patent and Exclusivity Data for Biologics.
- [4] Health Affairs. Value-Based Pricing and Biosimilars.
- [5] World Health Organization. Global Pharmaceutical Market Reports.
More… ↓
